SERB has a full range of internal research capabilities. Our clinical, regulatory, and quality teams work together to manage a robust pipeline of projects addressing high unmet medical needs in critical care and rare diseases.
We conduct research internally and through partnership with third-party research providers and independent investigators. These projects include:
- Developing new innovative products, such as new biologic antidotes that leverage our polyclonal antibody platform
- Supporting independent research in the form of Investigator Initiated Studies (IIS) that further the understanding of diseases and the role our therapies can play in treatment
- Incremental innovation to expand the usefulness of our products, such as registering products in a new geography or label extensions to address new indications
- Working with partners to bring new products to market or to support marketing authorisations in new territories
About our Polyclonal Antibody Platform:
SERB has developed a global manufacturing platform for the creation of broad-spectrum polyclonal antibodies. This polyclonal antibody technology has been used for over 20 years to produce two commercially available, FDA-approved products, and provides the opportunity to develop novel biologic therapies against a wide range of antigens. SERB is one of the few companies that can manufacture polyclonal antibodies at a commercial scale and with robust processes suitable for market authorisation in all territories.
The company is evaluating a promising pipeline of targets to address additional toxins, infectious diseases, biological agents, and drug toxicities. The most advanced project leveraging this platform is an antidote to counter ricin, a highly potent toxin for which there is no vaccine or therapeutic intervention available. SERB also has the flexibility, speed of response, and technical expertise to partner with government agencies to respond to emerging and future biosecurity risks.